Relapsing Multiple Sclerosis (RMS)

Also known as: Relapsed Multiple sclerosis / Multiple Sclerosis Relapse / Relapsing Multiple Sclerosis / Multiple sclerosis flare

DrugDrug NameDrug Description
DB00111DaclizumabHumanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.
DB11988OcrelizumabOcrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS. Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and significantly reduced quality of life [L1199]. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods, or remissions. Ocrelizumb was the first FDA-approved treatment for primary progressive multiple sclerosis (PPMS) [L1199]. PPMS accounts for 10-15% of the overall population of patients with MS, and involves gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions [A31741]. Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevustm for intravenous injection. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to interferon beta-1a [L1199]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab demonstrated lower rates of clinical and MRI progression than placebo [A31741].
DrugDrug NamePhaseStatusCount
DB05092CDP3231 / 2Completed1
DB06399Atacicept2Terminated2
DB00108Natalizumab2Terminated1
DB06650Ofatumumab2Not Yet Recruiting1
DB12612Ozanimod2 / 3Completed1
DB08868Fingolimod3Completed2
DB00060Interferon beta-1a3Active Not Recruiting2
DB00068Interferon beta-1b3Terminated1
DB06685Laquinimod3Terminated2
DB00788Naproxen3Completed1
DB11988Ocrelizumab3Active Not Recruiting2
DB11988Ocrelizumab3Recruiting1
DB06650Ofatumumab3Recruiting1
DB12612Ozanimod3Completed1
DB09122Peginterferon beta-1a3Completed3
DB12016Ponesimod3Active Not Recruiting1
DB08880Teriflunomide3Active Not Recruiting1
DB08880Teriflunomide3Recruiting3
DB08880Teriflunomide3Terminated1
DB11850Ublituximab3Recruiting2
DB08868Fingolimod4Recruiting1
DB00060Interferon beta-1a4Completed1
DB00108Natalizumab4Terminated1
DB09122Peginterferon beta-1a4Withdrawn1
DB00060Interferon beta-1aNot AvailableCompleted1
DB00060Interferon beta-1aNot AvailableRecruiting1
DB00108NatalizumabNot AvailableCompleted1
DB09153Sodium ChlorideNot AvailableCompleted1